The potential for antitumor vaccination in acute myelogenous leukemia

Robert J. Arceci

Research output: Contribution to journalReview article

Abstract

While many advances have been made in the treatment of patients with cancer, significant challenges that remain include tumor cell resistance and the toxicity associated with currently used intensive chemotherapeutic regimens. This is particularly true for patients with acute myelogenous leukemia (AML). Most patients with AML usually are able to achieve complete remission, but only a minority obtain long-term survival. In addition, much of the success achieved has been due to escalation of chemotherapeutic dosing and hematopoietic stem cell transplantation. There is thus a great need for improved therapies which would ideally be able to circumvent drug resistance and more specifically target leukemic cells. Advances in immunobiology over the past century have led to new hope for the development of immune mediated vaccine therapies for patients with cancer. This review focuses on the development of vaccine approaches for treatment of AML and some of the potential advantages and problems.

Original languageEnglish (US)
Pages (from-to)80-93
Number of pages14
JournalJournal of Molecular Medicine
Volume76
Issue number2
DOIs
StatePublished - Mar 9 1998

Keywords

  • Acute myelogenous leukemia
  • Cancer vaccines
  • Costimulation
  • Cytokines
  • Immunotherapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery
  • Genetics(clinical)

Fingerprint Dive into the research topics of 'The potential for antitumor vaccination in acute myelogenous leukemia'. Together they form a unique fingerprint.

  • Cite this